Velan Capital Investment Management LP Makes New Investment in Replimune Group, Inc. (NASDAQ:REPL)

Velan Capital Investment Management LP purchased a new stake in Replimune Group, Inc. (NASDAQ:REPL - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 181,367 shares of the company's stock, valued at approximately $2,196,000. Replimune Group accounts for 1.9% of Velan Capital Investment Management LP's portfolio, making the stock its 12th largest position. Velan Capital Investment Management LP owned 0.27% of Replimune Group as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in REPL. JPMorgan Chase & Co. grew its holdings in shares of Replimune Group by 3.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 249,349 shares of the company's stock worth $2,733,000 after purchasing an additional 8,074 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of Replimune Group by 14.7% during the 4th quarter. SG Americas Securities LLC now owns 26,291 shares of the company's stock worth $318,000 after purchasing an additional 3,374 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Replimune Group by 24.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,317 shares of the company's stock worth $198,000 after purchasing an additional 3,177 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of Replimune Group by 8.3% during the 4th quarter. Rhumbline Advisers now owns 95,465 shares of the company's stock worth $1,156,000 after purchasing an additional 7,317 shares in the last quarter. Finally, New York State Common Retirement Fund grew its holdings in shares of Replimune Group by 260.8% during the 4th quarter. New York State Common Retirement Fund now owns 43,204 shares of the company's stock worth $523,000 after purchasing an additional 31,231 shares in the last quarter. Institutional investors own 92.53% of the company's stock.

Insiders Place Their Bets

In other Replimune Group news, insider Konstantinos Xynos sold 7,952 shares of the company's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total transaction of $64,093.12. Following the completion of the transaction, the insider now owns 146,933 shares of the company's stock, valued at $1,184,279.98. This represents a 5.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Andrew Schwendenman sold 3,287 shares of the company's stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $8.05, for a total value of $26,460.35. Following the transaction, the chief accounting officer now directly owns 68,284 shares of the company's stock, valued at $549,686.20. The trade was a 4.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 74,907 shares of company stock worth $603,655 in the last ninety days. 8.80% of the stock is currently owned by insiders.

Replimune Group Stock Performance

REPL stock traded down $0.41 during midday trading on Friday, hitting $8.35. The company's stock had a trading volume of 1,461,131 shares, compared to its average volume of 926,127. The stock's 50-day moving average price is $8.63 and its 200 day moving average price is $11.21. The company has a quick ratio of 11.43, a current ratio of 11.43 and a debt-to-equity ratio of 0.14. Replimune Group, Inc. has a 1 year low of $4.92 and a 1 year high of $17.00. The stock has a market cap of $643.08 million, a price-to-earnings ratio of -2.72 and a beta of 0.68.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its earnings results on Thursday, May 22nd. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same quarter in the previous year, the company posted ($0.25) earnings per share. On average, equities analysts forecast that Replimune Group, Inc. will post -2.97 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently issued reports on REPL. JPMorgan Chase & Co. increased their target price on Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. HC Wainwright raised their price objective on Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Replimune Group presently has a consensus rating of "Buy" and an average price target of $19.43.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.